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ABSTRACT
Within the spectrum of autoimmune diseases,
Sjo¨gren’s syndrome and primary biliary
cholangitis are exemplary and can be coined as
chronic epithelitis based on their frequent
coexistence in clinical practice and the highly
specific immune-mediated injury of the small
bile ducts and the exocrine glands. The patho-
genic mechanisms underlying the diseases are
similar, with apoptosis being the key element
leading to organ-specific immune-mediated
injury directed against the small bile ducts and
salivary gland epithelia, respectively along with
similar epidemiological features, such as female
predominance and the age of onset in the fifth
decade of life. Indeed, novel insights into the
pathogenesis of the diseases have been obtained
in recent years, including a better definition of
the role of B and T cells, particularly Th17 cells,
and the mechanisms of autoantibody-mediated
tissue injury, with anti-mitochondrial antibod-
ies and SS-A/SS-B being identified as specific for
primary biliary cholangitis and Sjo¨gren’s syn-
drome, respectively. These findings have
opened the possibility to new targeted thera-
pies, but most clinical needs remain unmet,
particularly from a therapeutic standpoint
where options diverge, with bile acids being the
predominant treatment strategy in primary bil-
iary cholangitis and immunomodulators being
used to treat Sjo¨gren’s syndrome. Here we pro-
vide a comprehensive review of the most recent
findings on the pathogenesis, clinical manifes-
tations and therapeutic options for Sjo¨gren’s
syndrome and primary biliary cholangitis,
respectively, while stressing the common traits
between these conditions. Our cumulative
hypothesis is that similarities outnumber dif-
ferences and that this may prove advantageous
towards a better management of patients.
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INTRODUCTION
Sjo¨gren’s syndrome (SS) and primary biliary
cholangitis (PBC) are chronic organ-specific
autoimmune diseases that affect the exocrine
glands, especially the salivary and lacrimal
glands, and biliary epithelia, respectively, ulti-
mately leading to their progressive
immune-mediated destruction [1, 2].
The nomenclature of PBC has been recently
changed from cirrhosis to cholangitis to rectify
the inaccuracy of the term and to remove the
consequences of the cirrhosis stigma in patients,
as well as all of the misunderstandings, disad-
vantages and discrimination associated with this
misnomer[3–5]. This change was necessary given
recent dramatic improvements in the diagnosis,
prognosis and treatment of PBC, with the result
that the natural history of the disease is now
significantly better than previously. Currently,
an early diagnosis of PBC can be established with
the more accurate measurements of markers of
cholestasis and improvements in the detection of
the classic serologic hallmark, anti-mitochon-
drial antibodies (AMA), while treatment has
improved with the introduction of orthotopic
liver transplantation and ursodeoxycholic acid
(UDCA) treatment [6, 7].
Similar to other autoimmune diseases, SS
and PBC are diagnosed significantly more often
in women than in men, and it is the fifth decade
of life which is most frequently affected [8–11].
The two diseases often co-occur, and shared
genetic associations have been reported [12]. SS
can be primary or secondary to other systemic
autoimmune diseases; up to 43% of PBC
patients are also affected by another autoim-
mune condition, in particular chronic thy-
roiditis and systemic sclerosis [8, 13], with SS
found in up to 40% of patients with PBC [14].
On the other hand, as many as 20% of SS
patients manifest liver abnormalities [15].
Interestingly, when both diseases co-occur, few
cases are severe, as severe SS occurs in 10.5% of
PBC cases, while the PBC disease is usually
milder and at early stage (stage I–II at liver his-
tology) when SS is also present [14, 16].
From a serology standpoint, antinuclear
antibodies (ANA) are detected in both SS and
PBC, with a higher prevalence in SS compared to
PBC [17], while both conditions are associated
with the presence of disease-specific autoanti-
bodies, namely anti-Ro/SSA (Sjo¨gren’s-syn-
drome-related antigen A) and AMA, respectively.
In this review we discuss the most recent findings
on the immunopathogenesis of the PBC and SS
autoimmune epithelitis and focus on common
clinical manifestations and current and future
therapeutic options. This review is based on
previously conducted studies and does not
involve new studies of human or animal subjects
performed by the authors.
A COMMON
IMMUNOPATHOGENESIS
Both SS and PBC are chronic autoimmune dis-
eases associated with an immune-mediated
destruction of the epithelia [18]. Similar to
many autoimmune diseases, in SS and PBC
genetics and environmental factors interact to
result in disease onset [19, 20]. In this context,
over the past decades, mouse models of both SS
and PBC have been extensively developed and
studied, and they remain an invaluable tool in
the search for an understanding of disease
pathogenesis and to test novel therapeutics.
Mouse models for SS are categorized as sponta-
neous, genetically engineered or experimentally
induced animal models. Despite the numerous
achievements and advantages of mouse models,
no single mouse model has replicated each and
every aspect of human SS and PBC to date. In
addition, the initiation of the disease in mouse
models is highly artificial, especially in the
induced models, and the treatment is usually
initiated very early in the disease course, unlike
the clinical situation. Due to these limitations,
an appropriate control of animals for disease
onset and progression and cautious interpreta-
tion of the results are compulsory [21].
Genetics of SS and PBC
In the case of PBC, genetics play a predominant
role in disease susceptibility, as suggested by the
higher frequency of PBC among relatives of
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affected individuals than among the general
population. The term ‘familial PBC’ has been
coined to indicate families in which more than
one case of PBC occurs [22–25]. Conversely, in
SS there is a large variability in genetic factors in
ethnic groups, in particular within the human
leukocyte antigen (HLA) system [26]. As for
many autoimmune disorders, genetic factors are
known to play a decisive role in conferring PBC
susceptibility, but these are not related to a
single gene but to a complex multigene trait.
The relevance of the multifactorial genetic basis
in PBC has become more apparent recently,
including a higher concordance rate among
monozygotic (identical) than dizygotic twins
and the observation that peripheral lympho-
cytes from women with PBC preferentially lose
one X-chromosome [27, 28]. Indeed, PBC is not
only associated with the HLA DRB1*08 allele
but also with two protective alleles, HLA
DRB1*11 and DRB1*13 [12]. Furthermore, a
genome-wide association study confirmed that
HLA class II loci play a key role in PBC, and also
demonstrated that genes encoding for inter-
leukin (IL)-12 and its receptor are associated
with susceptibility to PBC [29], similar to what
has been reported for SS [30, 31].
Association of Infections with SS and PBC
Overall, it may be hypothesized that other fac-
tors, including epigenetics and exposure to
environmental triggers, such as infections or
xenobiotics, may play a role complementary to
genetics [32–37]. Infections are thought to
increase susceptibility to PBC and SS based on
molecular mimicry which ensues when an
infectious agent, bacterial or viral, presents
antigens with a significant amino acid similarity
to self-proteins [38]. In PBC, pyruvate dehy-
drogenase E2 (PDC-E2) shares a well-conserved
sequence across various species, with a high
degree of similarity to microbial PDC sequences
of Escherichia coli, Helicobacter pylori and others
[39, 40]. Novosphingobium aromaticivorans, a
ubiquitous xenobiotic-metabolizing Gram-neg-
ative bacterium, may represent the ideal candi-
date for PBC initiation because it contains
proteins with the highest degree of homology
to the major epitope of PDC-E2, while being
able to metabolize organic compounds and
estrogens. Moreover, N. aromaticivorans is rec-
ognized by PBC but not control sera [41]. Viral
agents have been postulated to be involved in
priming or triggering PBC and SS. In this con-
text, in SS, several viruses have been suggested,
particularly Herpesviridae, including Epstein–Barr
virus (EBV), cytomegalovirus (CMV) and herpes
simplex virus, all of which express tropism for
salivary and lacrimal glandular tissue [42]. EBV
genetic material is frequently detected in
peripheral lymphocytes, liver and salivary
glands from the majority of PBC patients [43],
and several lines of evidence support the notion
that the immune response against EBV-infected
epithelial cells play a role in the perpetuation of
salivary gland destruction in SS [44, 45]. The
presence of EBV in salivary gland and saliva
samples is associated with more severe SS and
marked abnormalities in immunoglobulin levels
[46]. EBV-DNA is also detected in up to 88% of
SS lacrimal glands [47]. CMV can induce a
SS-like pathology in the C57B1/6-lpr/lpr mice
model [48]. Persistent CMV infection induces an
alteration of cell surface expression in certain
tissues, initiating tissue destruction, and the
expression of autoantigens Ro/SSA, calreticulin
and major histocompatibility complex class I
proteins which can elicit an immune response
[49].
Immunobiology
Once the immune response is established, its
perpetuation and the development of autoim-
mune epithelitis takes several steps [50–53].
First, the epithelial cells become apoptotic, after
an initial stimulus, and aberrant autoantigens
are expressed on biliary and exocrine gland
epithelia, which may lead to an increased pre-
sentation to autoreactive T cells [12]. More
importantly, disease-specific molecules, i.e.
PDC-E2 and PDC-E2-like molecules, arehave
been demonstrated to be expressed in salivary
gland epithelial cells (SGEC) from 50% of
patients with SS and PBC [17, 54, 55]. Moreover,
SGEC and biliary epithelial cells (BEC) have the
unique capacity to release intact autoantigens
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after apoptosis via apoptotic blebs and bodies
[56–60]. In healthy tissues, apoptotic cells are
cleared by antigen presenting cells and neigh-
boring phagocytes, such as epithelial cells [61],
but in both SS and PBC this capacity is impaired
and may account for the prolonged availability
of autoantigens to stimulate an immune process
[62, 63]. More importantly, it has been shown
that BEC can phagocyte the apoptotic cells, but
then present the novel self-peptides and
pathologic epitopes on their membrane
[61, 64, 65].
Once the autoantigens have been presented,
a multi-lineage T- and subsequently B-cell
response develops. CD4? and CD8? T cells
directly infiltrate the target organs, as well as B
cells and macrophages, where also an increased
expression of proinflammatory cytokines,
chemokines and adhesion and costimulatory
molecules is found. Proinflammatory cytokines
play a crucial role in promoting systemic
inflammation and affect the proliferation and
maturation of the infiltrating lymphocytes
[12, 66, 67]. It has been reported that while BEC
produce IL-6 and tumor necrosis factor alpha
(TNF-a), minor SGEC cells express IL-1 and IL-6
[68]. Overall, an increased T-helper 1 (Th1) and
Th17 response is observed. T cells likely con-
tribute both directly and indirectly to tissue
damage and systemic manifestations through
production of cytokines (Th1, Th17 cells) and
maintenance of B cell-mediated responses (Tfh
cells) [69]. Elevated serum levels of inter-
feron-gamma, necessary for Th1 differentiation,
are detected in SS and PBC patients [70]. It has
recently been demonstrated that Th17 cells are
also involved in the pathogenesis of both dis-
eases. In SS, elevated levels of Th17-related
cytokines, i.e. IL-17, IL-6 and IL-12, are present
in serum, while transforming growth fac-
tor-beta, IL-6 and IL-23 are found in abundance
in minor salivary glands. A recent study has
further clarified that elevated IL-17F levels are
found in SS sera and are associated with
increased levels of immunoglobulin G (IgG) and
IgM, higher titers of ANA and anti-SSA anti-
bodies and lower levels of C3 and C4; in con-
trast, the serum IL-17A level was only increased
in patients with longer disease duration and
showed little correlation with clinical and
laboratory features [71]. In PBC, IL-12/
IL-23-mediated the Th1/Th17 signaling path-
way is involved in PBC and correlates with dis-
ease severity [72]. Interestingly, it has been
reported that the Th17 response may be present
in an early phase of the disease, since changes in
the expression profile of IL-17 and IL-23 are also
present in patients with pre-clinical SS and
non-autoimmune sicca syndrome [73].
Both SS and PBC are associated with altered
B-cell function, as exemplified by the presence
of serum autoantibodies and hyper-IgM levels
[74–77]. Indeed, therapeutic B-cell depletion
therapy may ameliorate both diseases and
decrease antigen presentation by B cells, but
current data are conflicting or inconclusive
[78–82]. Substantial evidence supports the role
of B-cell activating factor (BAFF) overexpression
leading to changes in B-cell differentiation, and
it could act as a potential biomarker of immune
dysregulation in autoimmune diseases [75].
BAFF levels are elevated in both PBC and SS,
especially if testing for anti-SSA/SSB is positive,
and correlate with histopathologic findings and
serum IgG levels [83]; however, this finding is
not specific as BAFF is elevated in several
autoimmune diseases [84]. The BAFF transgenic
mouse, developed and investigated in 1999 for
its phenotype of autoimmune-related condi-
tions, develops a SS-like condition, showing
infiltration in the salivary glands and loss of
secretory function and has provided insight
into the role of BAFF in prolonged B-cell activity
in SS-like autoimmune exocrinopathy [21].
Regarding PBC, a significant correlation has also
been reported between BAFF and cholestatic
enzyme levels, AMA titers, and disease stage
[85, 86]. Despite anti-SSA and AMA being highly
specific for these two diseases, no direct patho-
genic role has been demonstrated. Moreover,
B-cell hyperactivity in SS has been associated
with extraepithelial immune complex-mediated
manifestations, such as vasculitis, purpura,
glomerulonephritis and peripheral nephropa-
thy and the development of lymphoma. The
production of cryoglobulins and the deposition
of immune complexes to the affected tissues
represent the main mechanisms that drive the
pathogenesis of the extraepithelial manifesta-
tions [87].
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CLINICAL MANIFESTATIONS
The epithelia targeted in SS include exocrine
glands, i.e. lacrimal, salivary, sweat, mammary
and digestive system glands, with the latter
group including parts of the pancreas, liver and
gallbladder. In PBC, the small intrahepatic bile
ducts are mostly involved. However, in both
conditions, systemic manifestations may occur
with significant frequency. Most importantly,
approximately one-third of PBC patients will
manifest another autoimmune condition (i.e.
thyroid disease, other systemic autoimmune
rheumatic diseases), of which SS is among the
most frequent, while almost 5% of patients with
SS manifest biochemical and histologic features
of PBC [87].
Sjo¨gren’s Syndrome
Sjo¨gren’s syndrome can be coined an
organ-specific disease, as the main clinical
manifestations are oral and eye dryness which
are present at the time of diagnosis, with sys-
temic manifestations, such as vasculitis, that
sometimes may precede the classical sicca
symptoms. A significant percentage of patients
with SS complain of systemic dryness involving
the nose, trachea, vagina and skin, suggesting
that other glands are also affected in the context
of exocrine involvement [87]. Although glan-
dular manifestations vary in severity and may
affect the quality of life of patients with SS,
these have not been associated with increased
mortality and follow a rather stable clinical
course for many years. Systemic extraglandular
manifestations are present in 10–15% of
patients with SS, and are the result of the typical
lymphocytic infiltration around the epithelium
of target organs, such as the liver, kidney and
bronchi/bronchioles, or of the systemic form of
the disease presenting with the clinical picture
of vasculitis. In the kidney, the lymphocytic
infiltration of the interstitium and involvement
of tubular epithelium may lead to distal renal
tubular acidosis, which manifests as hypoka-
lemic hypochloremic metabolic acidosis with
normal anion gap and nephrolithiasis/nephro-
calcinosis [88]. Subclinical interstitial nephritis
is observed in 30% of patients with SS, but the
rate of overt disease ranges between 5 and 10%
[88]. The most common type of pulmonary
involvement is lymphocytic bronchitis/bron-
chiolitis, which affects nearly 20% of patients
and is characterized by dry irritant cough with
an obstructive respiratory pattern at functional
tests [87]. Extraglandular manifestations evolve
slowly with favorable outcome, although in
some cases, the ongoing pathologic process may
lead to severe organ impairment and end-stage
organ failure. Vasculitis manifests with palpable
purpura of the lower extremities and occasion-
ally leg ulcers in 10% of patients with SS.
Peripheral neuropathy due to inflammation of
the vasa vasorum affects 1% of patients with SS
and usually manifests as sensorimotor axonal
polyneuropathy and mononeuritis multiplex.
In the kidney, immune complexes are deposited
within the glomerulus to result in various clin-
ical manifestations, such as nephritic or
nephrotic syndrome [89]. The extraepithelial
manifestations appear late during the natural
history of SS and have been associated with
increased morbidity and mortality, in contrast
to PBC. Patients of this group have an increased
risk of developing lymphoproliferative disor-
ders, since palpable purpura and low C4 serum
levels have been found to be predictors of
lymphoma [87].
Primary Biliary Cholangitis
Symptoms of PBC in the early phases are clas-
sically described as fatigue and pruritus and
physical findings may include skin hyperpig-
mentation, hepatosplenomegaly and (rarely)
xanthelasmas, while end-stage symptoms are
those common to all types of liver cirrhosis,
including ascites, jaundice, hepatic
encephalopathy and upper digestive bleeding
[90, 91]. Nonetheless, a more pragmatic
approach is needed. Pruritus is becoming largely
a symptom of minor importance in current
clinical series and fatigue is a nonspecific
symptom present in 70% of patients with PBC,
particularly middle-aged women, that is often
overlooked. The severity of fatigue is indepen-
dent of the stage of PBC or its cholestatic
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features (pruritus), nor does it depend on psy-
chiatric factors. Pruritus has a similar frequency
as fatigue, being present in 70% of patients with
PBC and jaundice. It may long precede jaundice
onset and typically worsens at night, following
contact with wool, or in warm climates. Portal
hypertension is found in patients with PBC and,
importantly, does not require the presence of
liver cirrhosis as it can be pre-synusoidal. Over
one-half of untreated patients will develop
portal hypertension over a 4-year period; the
recommendations to diagnose and treat
PBC-associated portal hypertension are not dif-
ferent from those for other chronic liver
diseases.
Metabolic bone disease appears earlier in
patients with PBC when compared to sex- and
age-matched healthy individuals [92]. Hyper-
lipidemia is common in up to 85% of patients
with PBC, and both serum cholesterol and
triglyceride levels can be elevated. Interestingly,
however, such alterations are not accompanied
by an increased incidence of cardiovascular
events or atherosclerosis and do not correlate
with disease stage. Similar to other types of
cirrhosis, end-stage PBC can be complicated by
the occurrence of hepatocellular carcinoma,
and patients with intense nodular liver struc-
ture at ultrasound should be monitored by
computed tomography [2, 93, 94]. There is no
Table 1 The 2016 American College of Rheumatology/European League Against Rheumatism Sjo¨gren’s syndrome clas-
siﬁcation criteria
Item Weight/score
The classiﬁcation of primary Sjo¨gren’s syndrome (SS) applies to any individual who meets the inclusion criteriaa, does not
have any of the conditions listed as exclusion criteriab and has a score of C4 when the weights of the ﬁve criteria items
below are summed
Labial salivary gland with focal lymphocytic sialadenitis and focus score of C1 foci/4 mmc 3
Anti-SSA/Ro-positive 3
Ocular staining score C5 (or van Bijsterveld score C4) in at least one eyed, e 1
Schirmer’s test B5mm/5min in at least one eyed 1
Unstimulated whole saliva ﬂow rate B0.1mL/mind, f 1
a These inclusion criteria are applicable to any patient with at least one symptom of ocular or oral dryness, deﬁned as a
positive response to at least one of the following questions [1]: Have you had daily, persistent, troublesome dry eyes for more
than 3 months [2]? Do you have a recurrent sensation of sand or gravel in the eyes [3]? Do you use tear substitutes more
than three times a day [4]? Have you had a daily feeling of dry mouth for more than 3 months [5]? Do you frequently drink
liquids to aid in swallowing dry food?—or in whom there is suspicion of SS from the European League Against Rheumatism
Sjo¨gren’s syndrome Disease Activity Index questionnaire (at least one domain with a positive item)
b Exclusion criteria include prior diagnosis of any of the following conditions, which would exclude the diagnosis of
Sjo¨gren’s syndrome and participation in Sjo¨gren’s syndrome studies or therapeutic trials because of overlapping clinical
features or interference with criteria tests [1]: history of head and neck radiation treatment [2], active hepatitis C infection
(with conﬁrmation by PCR) [3], acquired immunodeﬁciency syndrome, [4] sarcoidosis, [5] amyloidosis [6], graft-ver-
sus-host disease [7], immunoglobulin G4-related disease
c The histopathologic examination should be performed by a pathologist with expertise in the diagnosis of focal lym-
phocytic sialadenitis and focus score count, using the protocol described by Daniel et al. [134]
d Patients who are normally taking anticholinergic drugs should be evaluated for objective signs of salivary hypofunction
and ocular dryness after a sufﬁcient interval without these medications in order for these components to be a valid measure
of oral and ocular dryness
e Ocular staining Score described by Whitcher et al. [135] and by the van Bijsterveld score described by van Bijsterveld
[136]
f Unstimulated whole saliva ﬂow rate measurement described by Navazesh and Kumar [137]
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increased frequency of lymphoproliferative dis-
eases in PBC patients.
DIAGNOSIS AND CLASSIFICATION
CRITERIA
The diagnosis of SS and PBC has to take into
account several features of the diseases, and
histology remains crucial, especially when test-
ing for serum autoantibodies is negative. To
assist the clinician in the diagnosis and, more
importantly, to harmonize patients enrolled in
clinical trials, criteria need to be followed for
both conditions [95].
Sjo¨gren’s Syndrome
The American College of Rheumatology (ACR)
and European League Against Rheumatism
(EULAR) developed their first SS classification
criteria in 2016 (Table 1). The sensitivity and
specificity of these criteria for clinician-ex-
pert-derived case/non-case status in the final
validation cohort were high, i.e. 96% [95% con-
fidence interval (CI) 92–98%] and 95% (95% CI
92–97%), respectively [96]. Serum autoantibod-
ies are a crucial tool for the diagnosis of SS and
may be present years before the manifestation of
connective tissue diseases [97], similar to other
connective tissue diseases. The most frequently
detected autoantibodies in SS are ANA, anti-Ro/
SSA, anti-La/SSB, rheumatoid factor (RF) and
anti-U1RNP (Table 2). Anti-Ro/SSA and anti-La/
SSB are considered to be hallmarks of the disease
and are associated with systemic disease, but they
are also present in the sera of patients with sys-
temic lupus erythematosus. The Ro/La particle is
a protein–RNA complex formed by the associa-
tion of the Ro60, and La/SSB proteins with small
cytoplasmic RNA (hyRNA). Various methods
Table 2 Commonly described autoantibodies in Sjo¨gren’s syndrome
Autoantibody Prevalence (%) Properties Clinical association
Anti-Ro/SSA 50–70 Disease marker Younger age at diagnosis
Severe and extraglandular disease
Pathogenic in congenital heart block
Anti-La/SSB 25–40 Disease marker Extraglandular disease
Pathogenic in congenital heart block
Rheumatoid factor 36–74 Phenotype marker Extraglandular disease
Anti-CCP 3–10 Phenotype marker Arthritis
Antimithocondrial antibodies 3–10 Phenotype marker Elevated liver enzymes
Anticentromere antibodies 3–27 Phenotype marker Raynaud’s phenomenon
SSA/SSB Sjo¨gren’s-syndrome-related antigen A/B, CCP cyclic citrullinated peptide
Table 3 Diagnostic criteria for primary biliary cholangitis
Parameters
Elevated alkaline phosphatase level of[29 ULN or elevated c-glutamyltransferase level of[5 9 ULN
Positivity for antimitochondrial antibodies
Chronic granulomatous cholangitis at liver biopsy
Diagnosis is deﬁned by the presence of at least 2 of the 3 criteria [138]
ULN Upper limit of normal
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have been used to detect anti-Ro/SSA and
anti-La/SSB antibodies, and while RNA precipi-
tation is considered to be the gold standard
method, other techniques, such as counter-im-
munoelectrophoresis, immunodiffusion and
enzyme linked immunosorbent assay are more
frequently used. Anti-Ro/SSA and anti-La/SSB
antibodies are detected in 50–70% of patients
with SS, depending on the method applied.
While anti-Ro/SSA is usually independent of
anti-La/SSB antibody, the contrary is rare [98]. Of
note, anti-La/SSB antibodies, along with ANA
and RF, have been removed from the classifica-
tion criteria, and some authors suggest that this
may mean that the guidelines are not adequate
for extraglandular disease, necessitating the def-
inition of ‘‘seronegative’’ SS [99]. Other autoan-
tibodies are associated with different
autoimmune diseases, but they may identify
patients with SS with unique clinical features.
Histology is the gold standard for SS diagnosis
and is necessary in patients who test negative for
anti-Ro/SSA and anti-La/SSB antibodies. There is
growing evidence to suggest that histology
should be performed in all SS patients (even those
who otherwise fulfil the criteria), as it provides
additional prognostic information with respect
to the future development of severe systemic
involvement and lymphoma [100]. Salivary
gland biopsy is most easily performed by labial
biopsy of the minor salivary glands, which is a
simple procedure that can be performed under
local anesthesia by a dentist/otolaryngologist
trained in the appropriate collection procedure,
with the collection of five to ten minor salivary
glands by blunt dissection via an incision
through normal-appearing mucosa [101].
Functional tests are of great help when there
is a suspicion of sicca syndrome. The Schirmer
test for dry eyes is easily performed in an out-
patient environment. Normal tear production
usually results in wetting of C15 mm of the strip
over a 5-min period, with B5 mm considered to
be positive (abnormal). Moreover, evaluation of
the ocular surface is most frequently performed
by an ophthalmologist, fluorescein is used to
determine the integrity of the corneal epithe-
lium, with rose bengal or lissamine green used
for evaluating the integrity of the conjunctiva.
Both dyes stain the same features of the ocular
surface, including mucus strands, filaments and
areas of epithelium unprotected by normal
mucin components of the glycocalyx [102].
Primary Biliary Cholangitis
The diagnosis of PBC is based on the presence of
two out of three internationally accepted crite-
ria, i.e., detectable serum AMA (titer [1:40),
increased enzyme levels indicating cholestasis
[i.e. alkaline phosphatase (ALP)] for[6 months
and a compatible or diagnostic liver histology
(Table 3). In a large number of cases (20–60%),
the diagnosis of PBC is established in the
absence of symptoms indicating a liver condi-
tion or cholestasis, and the proportion of
asymptomatic cases at diagnosis has been
increasing in recent years. At presentation, PBC
is suspected if a biochemical cholestatic pattern
(increased plasma ALP or c-glutamyltransferase)
is present, with no similar increase in plasma
aminotransferase levels. Serum IgM levels are
typically elevated in PBC patients, with no
correlation with AMA titers or levels of other
immunoglobulin subtypes. Once cirrhosis has
developed, biochemical alterations are similar
to those seen in other types of cirrhosis.
Serum AMA are highly specific for PBC and
can be detected in nearly 100% of patients
when sensitive diagnostic methodologies based
on recombinant antigens are used. In most
clinical settings, however, indirect immunoflu-
orescence techniques are used for initial
screening of the cases and these may provide
falsely positive or negative results [103–106].
AMA are directed against components of the
2-oxoacid dehydrogenase family of enzymes
within the mitochondrial respiratory chain,
most frequently the E2- and E3-binding protein
components of the pyruvate dehydrogenase
complex and the E2 components of the 2-oxo
glutarate dehydrogenase and branched-chain
2-oxo acid dehydrogenase complexes. In all
three antigens, epitopes contain the DKA motif,
with lipoic acid covalently bound to the lysine
(K) residue [107]. The pathogenic role of AMA is
highly likely, despite the apparent absence of a
clinical correlation and the observation that
animal models developing serum AMA do not
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develop PBC-like liver lesions [108]. Autoanti-
bodies other than AMA can be found in 76% of
PBC patients [109–111]. ANA can be found in
50% of PBC patients, with the most common
patterns being ‘‘nuclear rim’’ or ‘‘multiple
nuclear dots.’’ ANA-positive patients are more
frequently AMA-negative, possibly due to the
lack of a masking effect of these latter antibod-
ies in such sera. The pathogenic role of ANA in
PBC remains enigmatic, although cross-sec-
tional and longitudinal data demonstrate an
association between ANA positivity and a worse
prognosis [112].
Histology remains the gold standard for PBC
diagnosis and staging. The typical PBC histolog-
ical lesions can be classified in four stages. Stage I
manifests with portal tract inflammation with
predominantly lymphoplasmacytic infiltrates,
resulting in vanishing septal and inter-lobular
bile ducts (diameter\100 lm). At this stage, bile
duct obliteration and granulomas (possibly
found at all stages) are strongly suggestive of PBC.
In stage II, a periportal inflammatory infiltrate is
observed, and signs of cholangitis, granulomas,
and florid proliferation of ductules are typical.
Septal or bridging fibrosis in present in stage III,
with ductopenia (over half of the visible inter-
lobular bile ducts having vanished) and copper
deposition in periportal and paraseptal hepato-
cytes observed. Stage IV corresponds to frank
cirrhosis and cannot be discriminated from cir-
rhosis of other etiologies [113]. The observation
of eosinophils in the portal tract is a specific
finding in PBC histology.
CURRENT AND FUTURE
THERAPEUTIC OPTIONS
The treatment of SS and PBC, similar to that of
other autoimmune diseases, has dramatically
changed in recent years as a result of the
development of new targeted drugs.
Sjo¨gren’s Syndrome
The treatment of SS ranges from topic agents
aimed to alleviate sicca syndrome, secretagogue
agents and immunosuppressants. Dry eyes and
mouth remain the features which most impair
the quality of life and limit activity most in
patients with SS, and patient education is criti-
cal to successful management. In fact, patients
with mild, episodic dry eye can be managed
with modification of their environment, i.e.
avoiding dry or windy environments, and
activities of daily living.
Topical Treatments
The first line of therapy for dry eye in SS are
‘‘artificial tears’’, of which the main ingredients
are lubricants with a polymeric base or viscosity
agent. Topical cyclosporine 0.05% has been
used to treat dry eye disease. Although the
mechanism of action was initially thought to be
primarily mediated by inhibition of activation
of T-lymphocytes, further study has confirmed
that it has multiple inhibitory properties,
including the ability to inhibit apoptosis in
other cell types. The recommended therapy is
topical application of one drop of cyclosporine
in each eye twice daily [102]. With regard to dry
mouth, salivary substitutes are currently avail-
able for the amelioration of xerostomia; how-
ever, a Cochrane review found no strong
evidence that any topical therapy is effective for
either relieving the symptom of dry mouth or
preventing caries [114].
Secretogogues
The secretogogue oral pilocarpine, a muscarinic
receptor agonist, has been shown to be effective
in reducing symptoms and objective findings of
dry eye and mouth [115]; however, it can cause
uncomfortable side effects, such as nausea,
flushing, sweating, and urinary frequency, and
should be used with caution in patients with
cardiac disease or asthma because of the risks of
bradycardia and bronchospasm. To avoid these
effects, pilocarpine should be started at low
dose, i.e. 5 mg, and titrated upward as needed
and tolerated, to a maximum of 30 mg daily in
three or four divided doses [102].
Immunosuppressants
The treatment of SS with disease-modifying
agents is mainly empirical, and evidence-based
recommendations for the treatment of
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systemic disease manifestations are lacking.
No therapy has been shown to significantly
affect disease course. Hydroxychloroquine
(HCQ) is useful for the treatment of
extraglandular manifestations; however, a
recent randomized clinical trial showed that
HCQ was no better than placebo in improving
dryness, pain and fatigue in a cohort of 120
patients with SS during 24 weeks of treatment
[116]. Methotrexate is frequently used to treat
inflammatory arthritis, with little evidence to
support its use in SS [117]. Biologics targeting
TNFa have failed to achieve primary outcomes
in SS, while rituximab, an anti-CD-20 B-cell-
depleting therapy, had shown promising
results in reducing systemic disease manifes-
tations, including parotid swelling and pul-
monary and articular involvement
[78, 79, 118, 119] in selected cases. However,
the authors of a recent randomized clinical
trial has concluded that rituximab treatment
in SS is neither clinically nor cost-effective
[120]. The BAFF/BLyS antagonist belimumab,
currently approved for systemic lupus erythe-
matosus, has been evaluated in SS, and recent
data suggest that long-term use is effective in
reducing disease activity, while the salivary
flow, Schirmer test and the focus score of
salivary biopsy did not change [121]. Abata-
cept, an anti-CTLA4 biologic agent currently
approved for the treatment of rheumatoid
arthritis, has also been evaluated in patients
with SS; the main findings of these studies
show that this agent could also be effective for
treating SS features [122, 123].
Primary Bliary Cholangitis
Current treatments for PBC are currently based
on UDCA, which is the only approved drug for
this rare disease. To date, however, the mecha-
nism of action of UDCA is incompletely
understood, although depending on the various
phases of the disease, different therapies may be
effective [124–128].
During the early (pre-cirrhotic) phases of the
disease, short-term treatment with glucocorti-
coids might be effective, although there are
concerns about the safety of long-term use of
such medications. Budesonide, due to its high
first-pass metabolism, has minimum systemic
adverse effects, and, at 6–9 mg daily has been
demonstrated to be superior to UDCA both in
terms of histology and biochemical markers.
Other immunosuppressants, such as
methotrexate and azathioprine, have also been
suggested, and there is evidence supporting the
use of the latter in PBC patients with autoim-
mune hepatitis overlap syndrome. In recent
years mainly thanks to the better understanding
of PBC pathogenesis, new targeted therapies
have been tested, especially against the
IL-17/-23 axis with ustekinumab, a monoclonal
antibody against the p40 subunit. However,
albeit being associated with a modest decrease
in ALP after 28 weeks of therapy, it did not lead
to otherwise major changes in ALP [129]. Other
therapies targeting T cells, specifically trough
CTLA-4 with abatacept and with a CD40-an-
tagonist (FFP104), are under investigation
[130–132].
When the disease has already progressed and
bile is accumulated, obeticholic acid (OCA), an
analog of chenodeoxycholic acid, a bile acid
with a higher affinity to the Farnesoid X
receptor, has been shown in a recent Phase III
trial to decrease bile synthesis, promote secre-
tion and induce liver regeneration in animal
models [133]. In that same trial, OCA adminis-
tered with UDCA or as monotherapy for
12 months resulted in decreases from baseline
in ALP and total bilirubin levels that differed
significantly from the changes observed with
placebo [133].
Ultimately, UDCA remains the cornerstone
therapy of PBC, and dosages ranging from 13 to
15 mg/kg are currently used and lead to opti-
mum bile enrichment, with 50% of patients
achieving normalized ALP levels. Other
immunosuppressive treatments should be star-
ted only in combination with UDCA.
Liver transplantation is the ultimate treat-
ment for patients with end-stage PBC, with
survival rates of 92 and 85% at 1 and 5 years
after transplant, respectively. Recurrence is
common, with recurrence rates seemingly
influenced by certain immunosuppressive regi-
mens. The use of UDCA for recurrence is safe
and recommended.
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CONCLUSIONS
More data are now supporting the thesis that SS
and PBC are both immune-mediated epithelitis
with similar pathogenetic mechanisms. While
we are currently witness to a major converging
of the management options for these condi-
tions between rheumatologists and hepatolo-
gists, which ameliorates the therapeutic
choices, there remain several unmet needs,
including better treatment tailoring, earlier
diagnosis and the possibility to provide shared
treatments which may tackle both conditions.
We may surmise that the newly available lar-
ge-scale technological platforms for biomarker
discovery or single cell analysis should be
applied to PBC and SS to determine which
degree of similarity is indeed relevant for the
physician in 2017.
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